Eli Lilly plans to use some of its $7.3B cash pile to fund an “App Store” for biotech scientists, after opening a data center with 1,016 Blackwell chips in 2025
Mounjaro maker is collaborating with small biotechs on AI as a tool for drug discovery
Context & Ripple Effects
Eli Lilly’s latest AI push extends a sequence of investments rather than standing alone: it partnered with Nvidia on a Blackwell-powered pharma supercomputer and later announced a jointly funded AI drug lab.
Lilly has also been building external AI-discovery relationships, including with Isomorphic Labs and Insilico Medicine. Funding a scientist-facing application layer would connect its internal compute build-out with a broader network of smaller biotech collaborators.
First-order effects
- Lilly can direct part of its cash reserve toward software and services for biotech scientists, alongside the Blackwell-based data-center capacity it has already opened.
- Small biotech collaborators gain a potential route to use Lilly-backed AI tools in discovery work, while Lilly gains a more structured interface for working with those partners.
Second-order effects
- The move increases pressure on AI-drug-discovery vendors to show how their tools fit into pharmaceutical companies’ preferred compute, data, and collaboration environments rather than operating as standalone point solutions.
- Nvidia’s role becomes more strategically embedded if Lilly’s scientist-facing tools are built around the compute infrastructure and joint AI-lab effort the companies have already announced.
Third-order effects
- If other drugmakers follow, AI drug discovery could shift from bilateral vendor deals toward pharma-controlled platforms that combine computing capacity, internal research workflows, and selected external developers.
- That model could give large, well-capitalized pharmaceutical companies greater influence over which AI tools and partners reach their research organizations, though its durability will depend on whether platform access improves discovery outcomes rather than merely centralizing infrastructure.
The trend: Drugmakers are moving from experimenting with AI discovery partners to assembling vertically integrated AI ecosystems spanning chips, compute, software, and biotech collaboration.